Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes

Lung Cancer

Volumn 47, Issue 1, 2005, Pages 69-80

  Le Chevalier, T ^a   Scagliotti, G ^b   Natale, R ^c   Danson, S ^d   Rosell, R ^e   Stahel, R ^f   Thomas, P ^g   Rudd, R M ^d   Vansteenkiste, J ^h   Thatcher, N ⁱ   Manegold, C ^j   Pujol, J L ^k   Van Zandwijk, N ^l   Gridelli, C ^m   Van Meerbeeck, J P ⁿ   Crino, L ^o   Brown, A ^p   FitzGerald, P ^q   Aristides, M ^p   Schiller, J H ^r  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF TURIN   (Italy)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g HÔPITAL SAINTE MARGUERITE   (France)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^j Thoraxklinik   (Germany)

^k HÔPITAL ARNAUD DE VILLENEUVE   (France)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

^m S G MOSCATI HOSPITAL   (Italy)

ⁿ GHENT UNIVERSITY HOSPITAL   (Belgium)

^o BELLARIA HOSPITAL   (Italy)

^p M TAG   (United Kingdom)

^q NSW Australia   (Australia)

^r UNIVERSITY OF WISCONSIN MADISON   (United States)

more..

Author keywords

Chemotherapy; Gemcitabine; Meta analysis; Metastasis; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 10444237218     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.10.014     Document Type: Article

References (57)

1. D. Parkin, F. Bray, and J. Ferlay Estimating the world cancer burden: Globocan Int J Cancer 94 2001 153 156
2. S. Novello, and T. Le Chevalier Chemotherapy for non-small-cell lung cancer Part 1: early stage disease Oncology 17 2003 357 364
3. A. Juretic, H. Sobat, and M. Samija Combined modality therapy of non-small cell lung cancers Ann Oncol 10 Suppl. 6 1999 93 98
4. E.E. Vokes, S. Vijayakumar, and J.D. Bitran Role of systemic therapy in advanced non-small-cell lung cancer Am J Med 89 1990 777 786
5. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
6. J.P. Sculier, M. Paesmans, and P. Libert Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer European lung cancer working party Eur J Cancer 30A 1994 1342 1347
7. R.B. Natale Overview of current and future chemotherapeutic agents in non-small cell lung cancer Semin Oncol 24 2 Suppl. 7 1997 S7 S37
8. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
9. J.H. Schiller, D. Harrington, C.P. Belani The Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
10. K. Kelly, J. Crowley, and P.A. Bunn Jr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
11. R.P. Abratt, A. Sandler, and L. Crino Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery Semin Oncol 25 4 Suppl. 9 1998 35 43
12. M. Rinaldi, L. Crino, and G.V. Scagliotti A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial Ann Oncol 11 2000 1295 1300
13. A. Sandler First-line combination chemotherapy for advanced non-small cell lung cancer: the Eastern Cooperative Oncology Group and Southwest Oncology Group experience Semin Oncol 26 1999 44 51
14. F. Cardenal, M.P. Lopez-Cabrerizo, and A. Anton Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 17 1999 12 18
15. P. Zatloukal, L. Petruzelka, and M. Zemanova Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial Lung Cancer 41 2003 321 331
16. R.M. Rudd, N.H. Gower, and L.E. James Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 21 2002 292a [abstr 1164]
17. C. Sederholm Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG) Proc Am Soc Clin Oncol 21 2002 291a [abstr 1162]
18. G. Scagliotti, F. De Marinis, M. Rinaldi Italian Lung Cancer Project Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291
19. P. Comella, G. Frasci, and N. Panza Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group J Clin Oncol 17 1999 1526 1534
20. J.P. Van Meerbeeck, E.F. Smit, and P. Lianes A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 20 2001 308a [abstr 1228, now fully published as: Smit EF, Van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003; 21: 3909-17]
21. J.W. Chang, C. Liaw, and C. Chen Randomized phase II study of vinorelbine plus cisplatinum versus gemcitabine plus cisplatinum in advanced non-small cell lung cancer: a preliminary result Proc Am Soc Clin Oncol 20 2001 336a [abstr 1339]
22. L. Crino, G.V. Scagliotti, and S. Ricci Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project J Clin Oncol 17 1999 3522 3530
23. Danson S, Clemons M, Middleton M, et al. A randomised study of gemcitabine with carboplatin (GC) versus mitomycin, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). In: Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncologists, 2001, p. 1285 [Abstract].
24. C. Gridelli, C. Gallo, and F.A. Shepherd Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 2003 3025 3034
25. A.C. Grigorescu, I.N. Draghici, and C. Nitipir Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial Lung Cancer 37 2002 9 14
26. M.J. Melo, P. Barradas, and A. Costa Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC): mitomycin/ vinblastine/cisplatin (MVP) is no longer a therapeutic option Proc Am Soc Clin Oncol 21 2002 302a [abstr 1205]
27. B. Parente, A. Barroso, and S. Conde A randomized phase III study of gemcitabine and carboplatin versus vinorelbine and carboplatinum in advanced non-small cell lung cancer (NSCLC) Lung Cancer 29 Suppl. 1 2000 S61
28. A.B. Sandler, J. Nemunaitis, and C. Denham Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 18 2000 122 130
29. P. Thomas, G. Robinet, and G. Sylvie Randomized phase II study of carboplatin/gemcitabine versus cisplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC). (GFPC 99-01 study) Proc Am Soc Clin Oncol 21 2002 336a [abstr 1341]
30. Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care. Meta-analysis in context. London: British Medical Journal, 2001. [2nd ed. of Systematic Reviews, chapter 11]
31. A. Jadad, R. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
32. D. Moher, D. Cook, and S. Eastwood Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement Quality of reporting of meta-analyses Lancet 354 1999 1896 1900
33. M. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
34. A. Whitehead, and J. Whitehead A general parametric approach to the meta-analysis of randomized clinical trials Stat Med 10 1991 1665 1677
35. L. Crino, and C. Calandri Gemzar platinum combinations: phase III trials in non-small cell lung cancer Lung Cancer 38 2002 S9 S12
36. L. Crino, and F. Cappuzzo New platinum derivatives in advanced non-small cell lung cancer Suppl Tumori 1 2002 S24 S25
37. A. Sandler First-line combination chemotherapy for advanced non-small cell lung cancer: the Eastern Cooperative Oncology Group and Southwest Oncology Group experience Semin Oncol 26 1999 44 51
38. L. Crino, M. Clerici, and F. Figoli Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research Lung Cancer 12 Suppl. 1 1995 S125 S132
39. J. Waters, and M. O'Brien The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of the National Institute of Clinical Excellence (NICE) Br J Cancer 87 2002 481 490
40. A. Clegg, D. Scott, and M. Sidhu A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small cell lung cancer Health Technol Assess 5 2001 1 195
41. J. Deeks, D. Altman, and M. Bradburn Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis M. Egger Systematic reviews in health care. Meta-analysis in context 2001 BMJ Books London, UK
42. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
43. L.A. Stewart, and M.K. Parmar Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341 1993 418 422
44. P.A. Bunn Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20 Suppl. 18 2002 23 33
45. R. Raftopoulos, R.J. Gralla, and G. D'Auria Assessing the role of cisplatin dose and dose intensity in advanced non-small-cell lung cancer: a comprehensive review of randomized trials Proc Am Soc Clin Oncol 22 2003 645a [abstr 2595]
46. R.C. Lilenbaum, P. Langenberg, and K. Dickersin Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival Cancer 82 1998 116 126
47. P. Marino, A. Preatoni, and A. Cantoni Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study Lung Cancer 13 1995 1 12
48. P. Marino, A. Preatoni, and A. Cantoni Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer A meta-analysis Cancer 76 1995 593 601
49. PORT Meta-analysis Trialists Group Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials Lancet 352 1998 257 263
50. R.S. Pritchard, and S.P. Anthony Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer A meta-analysis Ann Intern Med 125 1996 723 729
51. J. Sakamoto, S. Teramukai, Y. Watanabe Japanese Society of Strategies for Cancer Research and Therapy Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer J Immunother 24 2001 250 256
52. J.P. Sculier, L. Ghisdal, and T. Berghmans The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature Br J Cancer 84 2001 1150 1155
53. P.J. Souquet, F. Chauvin, and J.P. Boissel Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer Lung Cancer 12 Suppl. 1 1995 147 154
54. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 1998 930 942
55. National Institutes of Health Consensus Development Panel. National institutes of health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93 979-89.
56. R. Rosell, G. Scagliotti, and K.D. Danenberg Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer Oncogene 22 2003 3548 3553
57. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139